Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity
Autor: | Stefano Massarini, Anna Ferrulli, Concetta Macrì, Livio Luzi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Adult Endocrinology Diabetes and Metabolism medicine.medical_treatment Population 03 medical and health sciences 0302 clinical medicine Endocrinology medicine Humans Obesity Deep transcranial magnetic stimulation Adverse effect education education.field_of_study business.industry Middle Aged Transcranial Magnetic Stimulation Clinical trial Transcranial magnetic stimulation 030104 developmental biology Treatment Outcome Tolerability Brain stimulation Anesthesia Adverse events Original Article Headaches medicine.symptom Safety business 030217 neurology & neurosurgery |
Zdroj: | Endocrine |
ISSN: | 1559-0100 1355-008X |
Popis: | Purpose Repetitive Transcranial Magnetic Stimulation (rTMS) has been demonstrated to be effective in body weight control in individuals with obesity. Most clinical trials on rTMS provided a reassuring safety profile. In the present work, we present an extensive analysis on both severe and mild Adverse Events (AEs) in obese individuals treated with rTMS. Methods We examined the intensity, duration, correlation with the treatment, up to 1 year after the end of rTMS treatment. Results Descriptive analysis included a total of 63 subjects undergoing a 5-week deep rTMS experimental treatment for obesity (age 48.3 ± 10.4 years; BMI 36.3 ± 4.4 kg/m2): 31 patients were treated with high-frequency rTMS (HF), 13 with low-frequency rTMS (LF), and 19 were sham treated (Sham). Thirty-two subjects (50.8%) reported a total of 52 AEs, including mainly moderate (51.9%) events. The most frequently reported side effects were headaches of moderate intensity (40.4%) and local pain/discomfort (19.2%) and resulted significantly more frequent in HF group compared to other groups (p Highlights A safety analysis in obese individuals treated with TMS did not reveal any unexpected safety concern up to 1 year after the end of the treatment. Only headache and local pain/discomfort have been significantly more frequent in the high-frequency TMS-treated group compared with low-frequency and sham-treated groups. TMS exhibits a good safety profile in the obese population potentially more susceptible to side effects of brain stimulation. |
Databáze: | OpenAIRE |
Externí odkaz: |